Cargando…
Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106372/ https://www.ncbi.nlm.nih.gov/pubmed/35574379 http://dx.doi.org/10.3389/fonc.2022.858426 |
_version_ | 1784708268205015040 |
---|---|
author | Braunstein, Zachary McLaughlin, Eric Ruiz, Miguel Wei, Lai Bumma, Naresh Benson, Don Devarakonda, Srinivas Chaudhry, Maria Khan, Abdullah Cottini, Francesca Hanel, Walter Baiocchi, Robert Chung, Catherine Addison, Daniel Couette, Nina Meara, Alexa Jarjour, Wael Porcu, Pierluigi Mishra, Anjali Reneau, John C. Rosko, Ashley E. Brammer, Jonathan E. |
author_facet | Braunstein, Zachary McLaughlin, Eric Ruiz, Miguel Wei, Lai Bumma, Naresh Benson, Don Devarakonda, Srinivas Chaudhry, Maria Khan, Abdullah Cottini, Francesca Hanel, Walter Baiocchi, Robert Chung, Catherine Addison, Daniel Couette, Nina Meara, Alexa Jarjour, Wael Porcu, Pierluigi Mishra, Anjali Reneau, John C. Rosko, Ashley E. Brammer, Jonathan E. |
author_sort | Braunstein, Zachary |
collection | PubMed |
description | T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. There was no survival difference in patients with CTCL or T-LGLL and concomitant PCD when treated with standard therapy directed at the T-cell malignancy when compared to historical controls. However, patients with PTCL and concomitant PCD had significantly inferior outcomes with rapid progression and worse OS and PFS at 1.7 years (p=0.006) and 4.8 months (p=0.08), respectively, when compared to historical controls for patients with PTCL, although the limited number of patients included in this analysis precludes drawing definitive conclusions. Treatment directed at the T-cell malignancy resulted in the eradication of the PCD clone in multiple patients (15.4%) including one with multiple myeloma (MM) who experienced a complete response after starting therapy directed at the T-cell malignancy. For patients with T-cell malignancies and concomitant PCD, treatment with standard T-cell-directed therapies is recommended based on this analysis with continued follow-up and monitoring of the concomitant PCD. Further studies are needed to definitively elucidate the increased risk of relapse in patients with PTCL and concomitant PCD, and larger, multi-center cohorts are needed to validate these findings across T-cell malignancies and PCDs. |
format | Online Article Text |
id | pubmed-9106372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91063722022-05-14 Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias Braunstein, Zachary McLaughlin, Eric Ruiz, Miguel Wei, Lai Bumma, Naresh Benson, Don Devarakonda, Srinivas Chaudhry, Maria Khan, Abdullah Cottini, Francesca Hanel, Walter Baiocchi, Robert Chung, Catherine Addison, Daniel Couette, Nina Meara, Alexa Jarjour, Wael Porcu, Pierluigi Mishra, Anjali Reneau, John C. Rosko, Ashley E. Brammer, Jonathan E. Front Oncol Oncology T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. There was no survival difference in patients with CTCL or T-LGLL and concomitant PCD when treated with standard therapy directed at the T-cell malignancy when compared to historical controls. However, patients with PTCL and concomitant PCD had significantly inferior outcomes with rapid progression and worse OS and PFS at 1.7 years (p=0.006) and 4.8 months (p=0.08), respectively, when compared to historical controls for patients with PTCL, although the limited number of patients included in this analysis precludes drawing definitive conclusions. Treatment directed at the T-cell malignancy resulted in the eradication of the PCD clone in multiple patients (15.4%) including one with multiple myeloma (MM) who experienced a complete response after starting therapy directed at the T-cell malignancy. For patients with T-cell malignancies and concomitant PCD, treatment with standard T-cell-directed therapies is recommended based on this analysis with continued follow-up and monitoring of the concomitant PCD. Further studies are needed to definitively elucidate the increased risk of relapse in patients with PTCL and concomitant PCD, and larger, multi-center cohorts are needed to validate these findings across T-cell malignancies and PCDs. Frontiers Media S.A. 2022-04-29 /pmc/articles/PMC9106372/ /pubmed/35574379 http://dx.doi.org/10.3389/fonc.2022.858426 Text en Copyright © 2022 Braunstein, McLaughlin, Ruiz, Wei, Bumma, Benson, Devarakonda, Chaudhry, Khan, Cottini, Hanel, Baiocchi, Chung, Addison, Couette, Meara, Jarjour, Porcu, Mishra, Reneau, Rosko and Brammer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Braunstein, Zachary McLaughlin, Eric Ruiz, Miguel Wei, Lai Bumma, Naresh Benson, Don Devarakonda, Srinivas Chaudhry, Maria Khan, Abdullah Cottini, Francesca Hanel, Walter Baiocchi, Robert Chung, Catherine Addison, Daniel Couette, Nina Meara, Alexa Jarjour, Wael Porcu, Pierluigi Mishra, Anjali Reneau, John C. Rosko, Ashley E. Brammer, Jonathan E. Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias |
title | Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias |
title_full | Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias |
title_fullStr | Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias |
title_full_unstemmed | Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias |
title_short | Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias |
title_sort | incidence, treatment, and survival of patients with t-cell lymphoma, t-cell large granular leukemia, and concomitant plasma cell dyscrasias |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106372/ https://www.ncbi.nlm.nih.gov/pubmed/35574379 http://dx.doi.org/10.3389/fonc.2022.858426 |
work_keys_str_mv | AT braunsteinzachary incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT mclaughlineric incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT ruizmiguel incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT weilai incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT bummanaresh incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT bensondon incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT devarakondasrinivas incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT chaudhrymaria incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT khanabdullah incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT cottinifrancesca incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT hanelwalter incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT baiocchirobert incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT chungcatherine incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT addisondaniel incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT couettenina incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT mearaalexa incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT jarjourwael incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT porcupierluigi incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT mishraanjali incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT reneaujohnc incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT roskoashleye incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias AT brammerjonathane incidencetreatmentandsurvivalofpatientswithtcelllymphomatcelllargegranularleukemiaandconcomitantplasmacelldyscrasias |